Platelet-derived growth factors enhance proliferation of human stromal stem cells

Lucarelli, Enrico; Beccheroni, Amira; Donati, Davide María; Sangiorgi, Luca; Cenacchi, Annarita; Vento, A.M. Del; Meotti, Carolina Degen; Bertoja, Annarosa Zambon; Giardino, Roberto; Fornasari, Pier Maria; Mercuri, Mario; Picci, Piero

doi:10.1016/s0142-9612(03)00114-5

Cited by 359 publications

(320 citation statements)

References 19 publications

Supporting

Mentioning

282

Contrasting

Unclassified

Order By: Relevance

“…However, as reported by other authors, the high number of GF contained in PRP and the identification of the exact combination among these factors that induce bone growth will require more time and effort. 8 The positive effects on bone healing of the combined treatments such as PRP þ BMSC, FDBA þ PRP, FDBA þ BMSC, and FDBA þ PRP þ BMSC was already evident at 2 weeks. These results were probably due to the effect of factors contained in PRP on BMSC (in group PRP þ BMSC) and of the presence of bone that significantly increased PRP and BMSC therapeutic effect because of the adjunctive osteoconductive action in the groups FDBA þ PRP and FDBA þ BMSC.…”

Section: Discussionmentioning

confidence: 97%

“…BMSC have receptors for the growth factors contained in PRP, and in vitro studies demonstrated that the addition of 10% PRP was sufficient to promote a marked BMSC proliferation. 8 Regarding bone grafts, adding PRP to graft materials was observed to significantly reduce the time required to promote graft consolidation, maturation, and improved trabecular bone density. 9 Therefore, the addition of autologous BMSC or PRP to FDBA provides an immediate source of viable osteogenic precursor cells and GF at the graft implantation site and may additionally provide a direct biological contribution to osteogenesis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet‐rich plasma, and freeze‐dried bone allografts, alone and in combination

Dallari

Fini

Stagni

et al. 2006

Journal Orthopaedic Research

156

View full text Add to dashboard Cite

The repair of confined trabecular bone defects in rabbits treated by autologous bone marrow stromal cells (BMSC), platelet-rich plasma (PRP), freeze-dried bone allografts (FDBA) alone and in combination (BMSC þ PRP; FDBA þ BMSC; FDBA þ PRP; FDBA þ PRP þ BMSC) was compared. A critical size defect was created in the distal part of the femurs of 48 adult rabbits. Histology and histomorphometry were used in the evaluation of healing at 2, 4, and 12 weeks after surgery. The healing rate (%) was calculated by measuring the residual bone defect area. Architecture of the newly formed bone was compared with that of bone at the same distal femur area of healthy rabbits. The defect healing rate was higher in PRP þ BMSC, FDBA þ PRP, FDBA þ BMSC, and FDBA þ PRP þ BMSC treatments, while lower values were achieved with PRP treatment at all experimental times. The highest bone-healing rate at 2 weeks was achieved with FDBA þ PRP þ BMSC treatment, which resulted significantly different from PRP (p < 0.05) and BMSC (p < 0.05) treatments. At 4 weeks, the bone-healing rate increased except for PRP treatment. Finally, the bone-healing rate of FDBA þ PRP, FDBA þ BMSC, and FDBA þ PRP þ BMSC was significantly higher than that of PRP at 12 weeks (p < 0.05). At 12 weeks, significant differences still existed between PRP, BMSC, and FDBA groups and normal bone (p < 0.05). These results showed that the combination of FDBA, BMSC and PRP permitted an acceleration in bone healing and bone remodeling processes. ß

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet‐rich plasma, and freeze‐dried bone allografts, alone and in combination

Dallari

Fini

Stagni

et al. 2006

Journal Orthopaedic Research

156

View full text Add to dashboard Cite

show abstract

“…This ability has made MSC a potential component of tissue engineering concepts. Recently, several research groups have been studying PLG as a matrix for tissue-engineering models because the activated PLG releases numerous platelet-derived growth factors [49,50].…”

Section: Tissue Engineeringmentioning

confidence: 99%

The use of autologous platelet–leukocyte gels to enhance the healing process in surgery, a review

et al. 2007

View full text Add to dashboard Cite

Background: The therapeutic use of autologously prepared, platelet-leukocyte-enriched gel (PLG) is a relatively new technology for the stimulation and acceleration of soft tissue and bone healing. The effectiveness of this procedure lies in the delivery of a wide range of platelet growth factors mimicking the physiologic wound healing and reparative tissue processes. Despite an increase in PLG applications, the structures and kinetics of this autogenously derived biologic material have not been observed. Methods: A review of the most recent literature was performed to evaluate the use of PLG in various surgical disciplines. Results: The review showed that the application of PLG has been extended to various surgical disciplines including orthopedics, cardiac surgery, plastic and maxillofacial surgery, and recently also endoscopic surgery. Conclusion: This review demonstrates the usefulness of PLG in a wide range of clinical applications for improvement of healing after surgical procedures.Key words: Growth factors -Leukocytes -Platelet gel -Wound healing Soft tissue wound healing and bone growth involve physiologic cascades in which cellular and hormonal factors play pivotal roles [1,2]. Some of these cascade components can be isolated from autologously drawn whole blood. Point-of-care devices can intraoperatively fractionate the autologous blood into platelet-poor plasma, platelet-leukocyte-rich plasma (P-LRP), and red blood cells [3,4]. The P-LRP fraction, a mixture of concentrated platelets and leukocytes, can be activated by (autologous) thrombin to create a viscous solution known as platelet-leukocyte gel (PLG). This platelet coagulum can be exogenously applied to soft wound tissues, bone, or synthetic bone as a spray or as a solid, clotted, gelatinous mass. The rationale for applying platelet gel is based on the delivery of platelet growth factors to tissues and on the fact that platelet a-granules, found inside the platelets, contain a variety of growth factors [5]. Platelet gel growth factors are peptides that promote cell proliferation, differentiation, chemotaxis, and the migration of various cells involved in both wound healing and bone growth [6,7].Recently, numerous P-LRP devices have become available for therapeutic use to stimulate and accelerate soft tissue and bone healing and to control postoperative wound bleeding. The rationale for applying PLG lies in the mimicking and accelerating of physiologic wound healing and reparative tissue processes.This article provides information on the results of electron microscopic imaging used to evaluate the content of PLG. Furthermore, because the use of PLG is a relatively new per-and/or perioperative biotechnological application, new and additional indications for the use of PLG are defined. New PLG applications are reviewed for different applications including cardiac surgery, general surgery, orthopedics and traumatology, cosmetic surgery, maxillofacial surgery, sports medicine, and endoscopic surgical procedures. Defining platelet-leukocyte-rich...

show abstract

“…24 Lucarelli et al found that 10% PRP induced marked bone marrow cell proliferation. 16 Other investigators have found that PRP enhances mesenchymal stem cell (MSC) proliferation.…”

Section: Introductionmentioning

confidence: 99%

Buffered Platelet-Rich Plasma Enhances Mesenchymal Stem Cell Proliferation and Chondrogenic Differentiation

Mishra

Tummala²,

King

et al. 2009

Tissue Engineering Part C: Methods

359

257

View full text Add to dashboard Cite

The success of tissue engineering applications can potentially be dramatically improved with the addition of adjuncts that increase the proliferation and differentiation of progenitor or stem cells. Platelet-rich plasma (PRP) has recently emerged as a potential biologic tool to treat acute and chronic tendon disorders. The regenerative potential of PRP is based on the release of growth factors that occurs with platelet rupture. Its autologous nature gives it a significant advantage in tissue engineering applications. To test whether PRP may be useful specifically for cartilage regeneration, a cell culture experiment was devised in which mesenchymal stem cells (MSCs) were grown in control media or media enhanced with inactivated, buffered PRP. Proliferation 7 days after PRP treatment was increased: 1.041 versus 0.199 for the control media cells ( p < 0.001). The messenger RNA (mRNA) level of the osteogenic marker RUNX2 was 52.84 versus 26.88 for the control group ( p < 0.005). Likewise the mRNA level of the chondrogenic markers Sox-9 and aggrecan was 29.74 versus 2.29 for the control group ( p < 0.001) and 21.04 versus 1.93 ( p < 0.001), respectively. These results confirm that PRP enhances MSC proliferation and suggest that PRP causes chondrogenic differentiation of MSC in vitro.

show abstract

Platelet-derived growth factors enhance proliferation of human stromal stem cells

Cited by 359 publications

References 19 publications

In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet‐rich plasma, and freeze‐dried bone allografts, alone and in combination

In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet‐rich plasma, and freeze‐dried bone allografts, alone and in combination

The use of autologous platelet–leukocyte gels to enhance the healing process in surgery, a review

Buffered Platelet-Rich Plasma Enhances Mesenchymal Stem Cell Proliferation and Chondrogenic Differentiation

Contact Info

Product

Resources

About